What is it about?
This is a narrative review for the current status of post operative treatment for locally advanced squamous cell carcinoma of head and neck (LA-ASCCHN). In this review, we introduced pivotal trials, current standard treatment and important ongiing trials for these patients.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Chemoradiotherapy with high-dose cisplatin is the standard treatment for post-operative treatment for the LA-SCCHN patients with high-risk factors for recurrence. However, there has been emerging evidence of chemoradiotherapy with weekly cisplatin for these patients. JCOG1008 shows non-inferiority of weekly cisplatin plus RT to high-dose cisplatin plus RT for these patients. And many trials using novel treatment such as immunotherapy and IAP inhibitors are ongoing to improve the prognosis for these patients.
Perspectives
Weekly cisplatin plus RT ia a standard treament option for post-operative high-risk patients with LA-SCCHN. Results of the trials of de-escalation strategy for post-operative HPV positive oropharyngeal cancer patients and the combination with novel drugs with post-operative RT/CRT are awaiting.
Naomi Kiyota
Kobe University Hospital
Read the Original
This page is a summary of: Current status and future perspective of postoperative treatment for locally advanced squamous cell carcinoma of the head and neck, Japanese Journal of Clinical Oncology, March 2024, Oxford University Press (OUP),
DOI: 10.1093/jjco/hyae029.
You can read the full text:
Contributors
The following have contributed to this page
